Short Communication

Long-term survival of the mouse ES cell-derived mast cell, MEDMC-BRC6, in mast cell-deficient *Kit<sup>W-sh/W-sh</sup>* mice

Shohei Shibagaki<sup>1,2</sup>, Satoko Tahara-Hanaoka<sup>1,3,\*</sup>, Takashi Hiroyama<sup>4</sup>, Yukio Nakamura<sup>4</sup>, and Akira Shibuya<sup>1,3</sup>

<sup>1</sup>Department of Immunology, Faculty of Medicine,

<sup>2</sup>Doctoral Program in Graduate School of Comprehensive Human Sciences, and

<sup>3</sup>Life Science Center of Tsukuba Advanced Research Alliance (TARA), University of

Tsukuba, 1-1-1 Ten-nodai, Tsukuba, Ibaraki 305-8575, Japan.

<sup>4</sup>Cell Engineering Division, RIKEN BioResource Center, 3-1-1 Koyadai, Tsukuba, Ibaraki 305-0074, Japan

\*Corresponding should be addressed to Satoko Tahara-Hanaoka, E-mail: <u>tokothr@md.tsukuba.ac.jp</u>

Running title: Mouse ES cell-derived mast cell line, MEDMC-BRC6 Key words: FccRI, degranulation, IgE-dependent anaphylaxis, TLR4, TLR2, **Abbreviations:** BMMC, bone marrow-derived cultured mast cell; ES cell, embryonic stem cell; FACS, fluorescence activated cell sorting; FccRI, high affinity receptor for IgE; GFP, green fluorescent protein; IgE, immunoglobulin E; IL-3, interleukin-3; LPS, lipopolysaccharide; MC, mast cell; OVA, ovalbumin; SCF, stem cell factor; TLR, toll-like receptor; TNP, 2, 4, 6-trinitrophenyl.

### Abstract

Mast cells (MCs) play pivotal roles in allergic reactions and the host defense against microbial infection through the IgE-dependent and IgE-independent signaling pathways. MC lines that can be analyzed both in vitro and in vivo would be useful for the study of MC-dependent immune responses. Here we investigated the functional characteristics of a mouse embryonic stem cell-derived MC-like cell line, MEDMC-BRC6. The cell line expressed FccRI and c-Kit and showed degranulation and production of inflammatory cytokines and chemokine, including TNF- $\alpha$ , IL-6 and MCP-1, upon crosslinking FccRI with IgE. These cytokines and chemokine were also produced by the cell line by stimulation of TLR2 and TLR4. MEDMC-BRC6 survived in the peritoneal cavity and the ear skin for at least 6months after the transfer into genetically compatible MC-deficient Kit<sup>W-sh/W-sh</sup> mice, in which systemic anaphylaxis was successfully induced. Thus, MEDMC-BRC6 cells represent a potent tool for investigating the functions of MCs in vitro and in vivo.

#### Introduction

Mast cells (MCs) play a central role in IgE-mediated immediate hypersensitivity reactions (1,2). MCs are also involved in the adaptive and innate immune response against pathogens through TLRs (3). MCs originate from hematopoietic stem cells and reside in nearly all vascularized tissues. Previous studies on the *in vitro* analyses of the functions of mouse MCs have mostly been conducted using the rat basophilic RBL-2H3 cell line and bone marrow-derived cultured MCs (BMMCs). However, RBL-2H3 cells carry a constitutively active form of the c-Kit receptor (4), which influences FccRI-signaling (5). BMMCs have been transferred into an MC-deficient mouse for *in vivo* studies (6). However, BMMCs from genetically engineered animals that exhibit an embryonic lethal phenotype are not available.

Embryonic stem (ES) cells are continuously growing stem cell lines that can be utilized for the generation of lineage-committed cells. MCs were also differentiated from ES cells *in vitro* (7-11). This *in vitro* technique for initiating the differentiation of ES cells into ES-derived MC is a powerful system for investigating the functions of MCs. It was reported that MCs generated from both wild-type and ES cells that are genetically manipulated *in vitro* can survive and display IgE-dependent passive cutaneous anaphylaxis *in vivo* at 3 weeks after intra-dermal injection into MC-deficient *Kitt<sup>W</sup>/Kitt<sup>W-v</sup>* mice (9). However, it remains unclear whether ES-derived MCs can be stably cultured over long periods *in vitro* and whether their properties are maintained during long-term culturing.

MEDMC-BRC6 is an established mouse ES-derived MC-like cell line that expresses FccRI and c-Kit and requires exogenous cytokines to survive (12). In the present study, we investigated the functional characteristics of MEDMC-BRC6 cells *in vitro* and *in vivo*.

### Materials and methods

#### Cells and reagents

The mouse ES-derived MC-like cell lines, MEDMC-BRC6, were purchased from RIKEN BioResource Center (BRC, Tsukuba, Japan) and were cultured as described previously (12). Briefly, cells were cultured in IMDM (Thermo Fisher Scientific, Waltham, MA, USA) containing the following materials: 15% fetal bovine serum (Sigma, St Louis, MO, USA); 10 µg/ml bovine insulin, 5.5 µg/ml human transferrin, and 5 ng/ml sodium selenite (ITS liquid MEDIA supplement; Sigma); 50 µg/ml ascorbic acid (Sigma); 0.45 mM Monothioglycerol (Wako, Tokyo, Japan); 100 unit/ml penicillin, 100 µg/ml streptomycin, and 2 mM L-glutamine (PSQ; Sigma). Mouse IL-3 (3 ng/ml; R&D Systems, Minneapolis, MN, USA) and mouse stem cell factor (SCF, 30 ng/ml; R&D Systems) were used for the culturing of MEDMC-BRC6 cells. MEDMC-BRC6 cells were frozen and thawed according to RIKEN BRC's instructions. MEDMC-BRC6 cells that stably expressed GFP were generated using a retroviral vector, pMXs (a kind gift from Dr. Toshio Kitamura, University of Tokyo), as described previously (13). The efficiency of retroviral transduction into MEDMC-BRC6 cells was  $\sim 30\%$ . The GFP<sup>+</sup> cells were sorted using a FACSAria cell sorter (BD Biosciences, Mountain View, CA, USA). The BMMCs were prepared by culturing bone

marrow cells with SCF (10 ng/ml) and IL-3 (4 ng/ml) for 4 weeks as described previously (13). The cells were cytocentrifuged at 500 rpm for 5 min (Shandon CytoSpin 3), and stained with Wright (Muto Pure Chemicals Co., Ltd., Tokyo, Japan), or 1.0% alcian blue at pH 2.5 (Wako) followed by 0.1% safranin O (Sigma). All images were acquired using a BZ-X710 microscope (Keyence, Osaka, Japan), and the data were analyzed using a BZ-H3 analyzer (Keyence). TLR2/TLR6-binding diacylated lipopeptide Pam2CSK4 (InvivoGen, San Diego, CA, USA) and TLR4 ligand LPS (Sigma) were used for stimulation of cells.

#### Quantitative reverse transcription PCR analysis

Total RNA was isolated from cell pellets (TRIzol, Thermo Fischer Scientific, Waltham, MA, USA) and used as a template for reverse transcription reactions (High-Capacity cDNA RT Kit, Applied Biosystems, Foster City, CA, USA). Quantitative PCR analysis of mouse MC proteases (MCPs) was performed by using an ABI7500 sequence detector (Applied Biosystems) and Power SYBR Green Master Mix (Applied Biosystems). The primers were:

*Mmcp-1* (forward,5'-ttcccttgcctggtccct-3'; reverse, 5'-gttttcccccagccagct-3')

*Mmcp-2* (forward, 5'-cattgcctagttcctctgacttca-3'; reverse, 5'-cctgttttcccccatccag-3')

Mmcp-4 (forward, 5'-cttctgactttatcaagccggg-3'; reverse, 5'-cactccagttcgccccc-3')
Mmcp-5 (forward, 5'-ctgcagtggcttcctgataa-3'; reverse, 5'-ggaattgcttttccacctca-3')
Mmcp-6 (forward, 5'-gcccagccaatcagcg-3'; reverse, 5'-ccagggccacttactctcaga-3')
Mmcp-7 (forward, 5'-catgcagcccccggt-3'; reverse, 5'-ttcccatgtgcctcctgtc-3')
Mmcp-8 (forward, 5'-ttcctcgggtattcaccagaa-3'; reverse, 5'-gggttgttgcaggagtttcatt-3')
Mmcp-9 (forward, 5'-gggtggcccatggtattgta-3'; reverse, 5'-cgggtgaagattgcaggg-3')
Mmc-cpa (forward, 5'-gctacacattcaaactgcctcct-3'; reverse, 5'-gagagggccgtggcaa-3')
Gapdh (forward, 5'-tggtgaaggtcggtgtgaac-3'; reverse, 5'-atgaaggggtcgttgatggc-3')
All experiments were performed in triplicate.

### Cytometric bead array analysis

The concentrations of inflammatory cytokines (TNF and IL-6) and chemokine (MCP-1) were measured by a cytometric bead array (CBA) analysis according to the manufacturer's instructions. Briefly, the culture supernatants (10  $\mu$ l) from stimulated cells (4-5 ×10<sup>5</sup> cells in 100-200  $\mu$ l) were mixed with 10  $\mu$ L of mixed captured beads from mouse Flex Set Cytometric Bead Array (Becton Dickinson, San Jose, CA, USA, Cat. No. 51-9005324, 51-9005236, 51-9005252), then detected with PE detection reagents (Becton Dickinson, Cat. No. 51-9004161, 51-9004153, 51-9004296). Flow

cytometric analysis was performed using the BD LSR Fortessa cell analyzer (BD Biosciences) and CBA analysis FCAP software (Becton Dickinson).

### Flow cytometry

The cells were stained with mAbs as indicated. Cells were treated with anti-CD16/32 mAb (2.4G2; TONBO Biosciences, San Diego, CA, USA) to avoid binding to Fc $\gamma$ R on ice for 10 min prior to incubation with the indicated combination of antibodies. Monoclonal antibodies against mouse c-Kit (2B8) and TLR2 (6C2) were purchased from BD Biosciences. Anti-mouse TLR4 (SA15-21) and CD11b (M1/70) were purchased from BioLegend. Anti-mouse Fc $\epsilon$ RI $\alpha$  (MAR-1) was purchased from eBiosciences. Anti-mouse CD45.2 (104) was purchased from TONBO Biosciences. Stained cells were acquired on a BD LSR Fortessa cell analyzer and were analyzed using the FlowJo software program (Tree Star, Inc., Ashland, OR, USA).

#### **Degranulation assay**

Degranulation was evaluated by measuring the release of  $\beta$ -hexosaminidase and by a flow cytometric analysis of the cell-surface exposure of CD107a (LAMP-1). LAMP-1 is an intracellular protein found on granule membranes that becomes exposed on MC surface upon degranulation (14). The cells were sensitized with the indicated concentration of IgE anti-2,4,6-trinitrophenyl (anti-TNP, C38-2; BD Biosciences) in culture medium for 15 h at 37°C and were then stimulated with the indicated concentration of TNP<sub>4</sub>-conjugated ovalbumin (OVA) in 100  $\mu$ l HEPES–Tyrode's buffer (pH 7.4) at 37°C. Cells that were stimulated with ionomycin (1  $\mu$ g/ml; Sigma) for 30 min were used as a positive control of degranulation. Culture supernatants or cells were collected at 30 or 10 minutes after the addition of the antigen, respectively. The culture supernatants were analyzed to detect the release of  $\beta$ -hexosaminidase and the percent degranulation was calculated as described previously (13). Cells were stained with anti-CD107a mAb (1D4B; BD Biosciences) and were analyzed by flow cytometry.

# **Reconstitution of** *Kit<sup>W-sh/W-sh</sup>* **mice with MEDMC-BRC6 cells**

MC–deficient  $Kit^{W-sh/W-sh}$  mice on the C57BL/6 background and C57BL/6 mice were purchased from RIKEN BRC and Clea Japan, respectively.  $Kit^{W-sh/W-sh}$  mice were reconstituted with  $2 \times 10^7$  of GFP-expressing MEDMC-BRC6 cells or  $10^7$  of BMMCs by intravenous injection. Three to 6 months after the injection, mice were analyzed for reconstitution of MC in the peritoneal cavity and ear pinnae by flow cytometry and the stomach by histology. Mouse ear pinnae were treated and stained as described previously (15,16). Briefly, ears were treated with enzyme mixture containing collagenase II and DNase I (400 U/ml and 50 U/ml, respectively; Worthington Biochemical, Lakewood, NJ, USA) for 1 h at 37°C with shaking, then stained with indicatedmAbs. Peritoneal MCs and ear skin MCs were positive for both FccRI and c-Kit. To analyze tissue MC in the stomach, 3 µm paraffin sections of fixed tissues with 4% paraformaldehyde were stained with 0.05% toluidine blue O (Chroma-Gesellschaft, Schmid & Co., Stuttgart, Germany) or with 1 % alcian blue, pH2.5 (Wako) in 3% acetic acid for 30 minutes followed, after washing, by 0.1% safranin O (sigma) for 5 minutes.

#### Passive systemic anaphylaxis

*Kit<sup>W-sh/W-sh</sup>* mice that had been intravenously injected with  $2 \times 10^7$  cells of GFP-expressing MEDMC-BRC6 cells 6 months previously were sensitized with an intravenous injection of mouse IgE anti-TNP (20 µg; C38-2; BD Biosciences). Twenty-four hours later, the mice were challenged with an intravenous injection of TNP<sub>6</sub>-OVA (1 mg). After the antigen challenge, the rectal temperatures were measured every 5 min for 60 min using a digital thermometer (Shibaura Electronics, Tokyo, Japan). The mice used in all of the experiments were 8 to 13-week-old males and had been bred in the specific pathogen-free facilities at the University of Tsukuba. All

animal experiments in this study were carried out humanely, and all efforts were made to minimize suffering after receiving approval from the Animal Ethics Committee of the Laboratory Animal Resource Center, University of Tsukuba (Permit Number: 16–281), and in accordance with Fundamental Guideline for Proper Conduct of Animal Experiment and Related Activities in Academic Research Institutions under the Jurisdiction of the Ministry of Education, Culture, Sports, Science and Technology.

### Statistical analysis

The results were expressed as mean  $\pm$  SEM. The values were analyzed by parametric ANOVA. P values of <0.05 were considered to indicate statistical significance.

### **Results and discussion**

#### The FccRI-mediated activation of signaling in MEDMC-BRC6 cells

MEDMC-BRC6 cell was generated by culturing C57BL/6-derived ES cells (BRC6) on feeder cells (OP9 cells) with cytokines (SCF, EPO, and IL-3) (12). MEDMC-BRC6 cells exhibit mast cell (MC)-like phenotypes because they harbor basic granules (Fig. 1A) and express high-affinity receptor for IgE, FccRI and c-Kit on their cell surface (Fig. 1B) (12). However, the number and size of granules in the cytoplasm of MEDMC-BRC6 cells were smaller and the expression level of FccRI and c-Kit was lower than those of BMMCs (Fig. 1A), suggesting that MEDMC-BRC6 cells were immature compared with BMMCs. Similarly to bone BMMCs, MEDMC-BRC6 cells require both IL-3 and SCF for their survival and proliferation (12). However, their functions remain unclear. To characterize the phenotype of MEDMC-BRC6 cells, we stained MEDMC-BRC6 cells and BMMCs with alcian blue followed by safranin O. Mucosal MCs (MMCs) are preferentially stained with alcian blue due to the predominance of chondroitin sulphate. In contrast, safranin O rather than alcian blue preferentially stains connective tissue MCs (CTMC) due to the predominance of heparin (17). While BMMCs were positive for alcian blue, but not safranin O, MEDMC-BRC6 cells were positive for both alcian blue and safranin O (Fig. 1C), suggesting that

MEDMC-BRC6 had both characteristics of MMCs and CTMCs. Classification of CTMC and MMC can be determined by the expression of mouse MC secretory granule proteases (mMCPs) (18). To further phenotypically characterize MEDMC-BRC6 cells, we examined the relative gene expression levels of mMCPs in MEDMC-BRC6 and BMMC by quantitative reverse transcription PCR analyses. MEDMC-BRC6 cells expressed lower levels of mMCP-1, -2, -4, -5, -6, -7, -8, -9, and MC–carboxypeptidase A (MC-CPA) than did BMMCs (Fig. 1D), consistent with the results of morphological and phenotypical analyses (Fig. 1A), suggesting again that MEDMC-BRC6 cells were immature compared with BMMCs.

To clarify whether MEDMC-BRC6 cells can transduce signals via FceRI, the cells were sensitized with an anti-TNP IgE antibody and then stimulated with various concentrations of TNP-conjugated OVA. Stimulation of MEDMC-BRC6 cells as well as BMMCs sensitized with an anti-TNP IgE with the TNP-conjugated OVA antigen induced degranulation, as determined by CD107a expression and  $\beta$ -hexosaminidase release (Fig. 2A and B). These results indicated that although the degranulation was less in MEDMC-BRC6 cells compared with BMMCs, FceRI mediated an activating signal for degranulation in MEDMC-BRC6 cells. Next, we measured the production of proinflammatory cytokines and chemokine, including TNF- $\alpha$ , IL-6, and MCP-1 at 24 h

after antigen stimulation using a CBA. In accordance with the results of the degranulation experiment, MEDMC-BRC6 cells secreted inflammatory cytokines and chemokines upon crosslinking FceRI although the amounts of secreted cytokines and chemokines were less in MEDMC-BRC6 cells compared with BMMCs (Fig. 2C). Together, these results suggest that although the strength of signal through FceRI in MEDMC-BRC6 cells seemed to be lower than that in BMMCs, MEDMC-BRC6 cells can be utilized to investigate the FceRI-mediated signaling pathway in MCs *in vitro*.

#### TLR-mediated signaling in MEDMC-BRC6 cells

MCs are also activated through TLR-mediated signaling (19) and play an important role in the host defense against pathogens (20). Next, we examined the expression of TLR2 and TLR4 on MEDMC-BRC6 cells by flow cytometry and found that they expressed both TLRs (Fig. 3A and B). The cells were then stimulated with TLR2–TLR6-binding diacylated polypeptides, Pam2CSK4 or the TLR4 ligand, LPS. MEDMC-BRC6 cells, as well as BMMCs secreted inflammatory cytokines, including TNF- $\alpha$ , IL-6, and MCP-1 in response to stimulation with Pam2CSK4 (Fig. 3C) or LPS (Fig. 3D). Although, the expression of TLR2 on BMMCs was hardly detected by flow cytometry, the production of cytokines was induced in a dose-dependent manner of Pam2CSK4. Nonetheless, these results indicate that MEDMC-BRC6 cells can be used to investigate the signaling pathways mediated by TLR2 and TLR4 in MCs *in vitro*.

### MEDMC-BRC6 cells survive in MC-deficient mice

MEDMC-BRC6 cells are differentiated from mouse ES cells with a C57BL/6 background and require exogenous IL-3 and SCF for their survival (12). Based on these observations, we hypothesized that—similarly to BMMCs—MEDMC-BRC6 cells may survive in MC-deficient mice with a C57BL/6 background without exhibiting tumorigenicity in vivo. To achieve this, MC-deficient Kit<sup>W-sh/W-sh</sup> mice with a C57BL/6 background was intravenously injected with  $2 \times 10^7$  MEDMC-BRC6 cells, which had been retrovirally transduced with GFP.  $Kit^{W-sh/W-sh}$  mice transplanted with 10<sup>7</sup> of BMMCs were generated as a control. We analyzed the MCs in the peritoneal cavity fluid (PEC) and ear skin by flow cytometry and found that in C57BL/6 mice, 1–3% of the CD11b<sup>-</sup> cells in the PEC and 4–7% of the CD45<sup>+</sup> CD11b<sup>-</sup> cells in the ear skin were FceRI<sup>+</sup>c-Kit<sup>+</sup> MCs (Fig. 4A and B). In accordance with previous reports, no FceRI<sup>+</sup>c-Kit<sup>+</sup> cells were detected in the PEC or ear skin of *Kit<sup>W-sh/W-sh</sup>* mice (Fig. 4A and B) (6). However, at 24 weeks after the transfer of MEDMC-BRC6 cells into Kit<sup>W-sh/W-sh</sup> mice, we detected FceRI<sup>+</sup>c-Kit<sup>+</sup> cells in the PEC (Fig. 4A). Similarly to BMMCs,

MEDMC-BRC6 cells in the peritoneal cavity of Kit<sup>W-sh/W-sh</sup> mice were detected at 12 weeks after the transfer. Previous study demonstrated that intravenous injection of BMMCs did not result in reconstitution of MC in the ear skin of *Kit<sup>W-sh/W-sh</sup>* mice (6). Consistently, we also did not detect MC in the ear skin of Kit<sup>W-sh/W-sh</sup> mice with intravenous injection of BMMC at 12 and 24 weeks after the transfer (data not shown). However, at 24 weeks after the transfer of MEDMC-BRC6 cells into Kit<sup>W-sh/W-sh</sup> mice, we could detect FccRI<sup>+</sup>c-Kit<sup>+</sup> cells in the ear skin (Fig. 4B), which might be dependent on the characteristic of MEDMC-BRC6 cells with the safranin O-positive phenotype that is also observed in CTMC locating primarily in the skin. Therefore, we addressed whether MEDMC-BRC6 cells with the characteristic of the safranin O-positive phenotype survive in the stomach, where MC shows the MMC phenotype positive for alcian blue but negative for safranin O in wild-type mice (Fig 4D). While Kit<sup>W-sh/W-sh</sup> mice that received BMMCs intravenously showed the recruitment of MCs positive for alcian blue, but not safranin O, into the stomach at 12 weeks after the transfer, MCs observed in the stomach of Kit<sup>W-sh/W-sh</sup> mice that received MEDMC-BRC6 cells showed the safranin O, but not alcian blue, -positive phenotype (Fig. 4D). This result suggests that MCs in the stomach of MEDMC-BRC6-transferred mice exhibit the CTMC-like phenotype. No tumors were observed in those mice (data not shown). These results

indicate that MEDMC-BRC6 cells can survive for at least 6 months without tumorigenicity *in vivo*.

#### MEDMC-BRC6 cells compensate for the function of MCs in MC-deficient mice

Since MEDMC-BRC6 cells were adapted in vivo, we next assessed whether MEDMC-BRC6 cells in Kit<sup>W-sh/W-sh</sup> mice could orchestrate typical IgE-dependent and MC-dependent passive systemic anaphylaxis. Kit<sup>W-sh/W-sh</sup> mice before and 6 months after the transfer with GFP-expressing MEDMC-BRC6 cells as well as wild type-mice were passively sensitized with IgE antibodies against TNP and then challenged with an intravenous injection of TNP-conjugated OVA (TNP-OVA). We measured the rectal temperature, an indicator of passive systemic anaphylaxis, every 5 min after the antigen challenge. The IgE-sensitized wild-type mice showed a progressive decrease in rectal temperature within 20 min after the antigen challenge, whereas the Kit<sup>W-sh/W-sh</sup> mice did not show a decrease in rectal temperature (Fig. 4E). This finding was consistent with previous observations (13). As we expected, Kit<sup>W-sh/W-sh</sup> mice transferred with GFP-expressing MEDMC-BRC6 cells showed a progressive decrease in rectal temperature at 24 weeks after the transfer (Fig. 4E). These results indicate that MEDMC-BRC6 cells can be utilized for the systemic analysis of the FccRI-mediated functions of MCs in vivo.

In the present study, we demonstrated that gene-manipulated MEDMC-BRC6 cells survive and compensate for the IgE-dependent functions of MCs in MC-deficient mice without displaying tumorigenicity. These properties were stable and were observed continuously for >1 year after the induction of their differentiation from ES cells. Moreover, the doubling time of MEDMC-BRC6 cells was  $17 \pm 0.2$  h, which was 3 to 5-fold faster than that of BMMCs. The efficiency of retroviral transduction into MEDMC-BRC6 cells was ~30%. Thus, large numbers of genetically manipulated MCs can be ready for use in a short period, and their physiological role can be investigated systemically *in vivo*. Importantly, intravenous injection of MEDMC-BRC6 cells may be a useful material to investigate the function of MC, particularly in the skin, *in vivo* as well as *in vitro*.

### Funding

This work was supported in part by grants provided by Japan Society for the Promotion of Science (KAKENHI) (grant numbers 15H04862 and 15K15319 to S.T.–H.).

## Acknowledgements

We thank S. Tochihara and Y. Nomura for their valuable secretarial assistance.

## Author contributions

S.S. did all of the experiments and analyzed the data; T.H. and Y.N. contributed materials tools; S.T.–H. designed experiments, analyzed the data and wrote the manuscript; and A.S. supervised the overall project. All authors contributed to the critical review of the manuscript.

### **Conflicts of Interest statement:**

The authors declare no conflicts of interest.

# References

- 1 Galli, S. J. 2000. Mast cells and basophils. *Curr Opin Hematol* 7:32.
- 2 Schwartz, L. B. 1994. Mast cells: function and contents. *Current opinion in immunology* 6:91.
- 3 Marshall, J. S. 2004. Mast-cell responses to pathogens. *Nat Rev Immunol* 4:787.
- 4 Tsujimura, T., Furitsu, T., Morimoto, M., Kanayama, Y., Nomura, S., Matsuzawa, Y., Kitamura, Y., and Kanakura, Y. 1995. Substitution of an aspartic acid results in constitutive activation of c-kit receptor tyrosine kinase in a rat tumor mast cell line RBL-2H3. *International archives of allergy and immunology* 106:377.
- 5 Hundley, T. R., Gilfillan, A. M., Tkaczyk, C., Andrade, M. V., Metcalfe, D. D., and Beaven, M. A. 2004. Kit and FcepsilonRI mediate unique and convergent signals for release of inflammatory mediators from human mast cells. *Blood* 104:2410.
- 6 Grimbaldeston, M. A., Chen, C.-C., Piliponsky, A. M., Tsai, M., Tam, S.-Y., and Galli, S. J. 2005. Mast Cell-Deficient W-sash c-kit Mutant KitW-sh/W-sh Mice as a Model for Investigating Mast Cell Biology in Vivo. *The American Journal of Pathology* 167:835.
- 7 Wiles, M. V. and Keller, G. 1991. Multiple hematopoietic lineages develop from embryonic stem (ES) cells in culture. *Development* 111:259.
- 8 Keller, G., Kennedy, M., Papayannopoulou, T., and Wiles, M. V. 1993. Hematopoietic commitment during embryonic stem cell differentiation in culture. *Mol Cell Biol* 13:473.
- 9 Tsai, M., Wedemeyer, J., Ganiatsas, S., Tam, S. Y., Zon, L. I., and Galli, S. J. 2000. In vivo immunological function of mast cells derived from embryonic stem cells: an approach for the rapid analysis of even embryonic lethal mutations in adult mice in vivo. *Proc Natl Acad Sci U S A* 97:9186.
- 10 Tsai M, T. S., Wedemeyer J, Galli S. 2002. Mast cells derived from Embryonic stem cells: a model system for studying the effects of genetic manipulations on mast cell development, phenotype, and function in vitro and in vivo. *International Journal of Hematology* 75:345.
- 11 Garrington, T. 2000. MEKK2 gene disruption causes loss of cytokine production in response to IgE and c-Kit ligand stimulation of ES cell-derived mast cells. *The EMBO Journal*.
- Hiroyama, T., Miharada, K., Sudo, K., Danjo, I., Aoki, N., and Nakamura, Y.
   2008. Establishment of mouse embryonic stem cell-derived erythroid progenitor

cell lines able to produce functional red blood cells. PLoS One 3:e1544.

- Hitomi, K., Tahara-Hanaoka, S., Someya, S., Fujiki, A., Tada, H., Sugiyama, T., Shibayama, S., Shibuya, K., and Shibuya, A. 2010. An immunoglobulin-like receptor, Allergin-1, inhibits immunoglobulin E-mediated immediate hypersensitivity reactions. *Nat Immunol* 11:601.
- Grutzkau, A., Smorodchenko, A., Lippert, U., Kirchhof, L., Artuc, M., and Henz,
  B. M. 2004. LAMP-1 and LAMP-2, but not LAMP-3, are reliable markers for activation-induced secretion of human mast cells. *Cytometry A* 61:62.
- 15 Kanemaru, K., Noguchi, E., Tokunaga, T., Nagai, K., Hiroyama, T., Nakamura, Y., Tahara-Hanaoka, S., and Shibuya, A. 2015. Tie2 Signaling Enhances Mast Cell Progenitor Adhesion to Vascular Cell Adhesion Molecule-1 (VCAM-1) through alpha4beta1 Integrin. *PLoS One* 10:e0144436.
- 16 Tsurusaki, S., Tahara-Hanaoka, S., Shibagaki, S., Miyake, S., Imai, M., Shibayama, S., Kubo, M., and Shibuya, A. 2016. Allergin-1 inhibits TLR2-mediated mast cell activation and suppresses dermatitis. *Int Immunol* 28:605.
- 17 Enerback, L. 1966. Mast cells in rat gastrointestinal mucosa. 2. Dye-binding and metachromatic properties. *Acta Pathol Microbiol Scand* 66:303.
- 18 Pejler, G., Ronnberg, E., Waern, I., and Wernersson, S. 2010. Mast cell proteases: multifaceted regulators of inflammatory disease. *Blood* 115:4981.
- 19 Sandig, H. and Bulfone-Paus, S. 2012. TLR signaling in mast cells: common and unique features. *Front Immunol* 3:185.
- 20 Dawicki, W. and Marshall, J. S. 2007. New and emerging roles for mast cells in host defence. *Current opinion in immunology* 19:31.

### **Figure legends**

Fig 1. The phenotypic analyses of MEDMC-BRC6 cells

Cytospins of MEDMC-BRC6 cells and BMMCs were stained with Wright (A) or with alcian blue followed by safranin O (C). (B) Flow cytometric analysis of cell-surface expressions for FccRI and c-Kit. The data are shown as 5% probability contour plots. (D) Quantitative reverse transcription PCR analysis of MCPs and CPA. The relative gene expression levels were determined in triplicate. GAPDH, glyceraldehyde 3-phosphate dehydrogenase (used as an internal control for normalization). The figures are representative results of two independent experiments.

#### Fig 2. FccRI-mediated signaling in MEDMC-BRC6 cells

(A) MEDMC-BRC6 cells and BMMCs were sensitized with the anti-TNP IgE mAb, and then challenged with the indicated concentrations of TNP<sub>4</sub>-conjugated OVA antigen. (A) The cells were stained with mAbs against CD107a and c-Kit at 10 min after antigen stimulation and were analyzed by flow cytometry (n = 3). The proportion of CD107a<sup>+</sup> c-Kit<sup>+</sup> cells is shown. (B) The culture supernatants were collected from at 30 min after the antigen challenge and  $\beta$ -hexosaminidase activity was determined (n = 3). (C) The culture supernatants were collected from (A) at 24 h after antigen challenge, and cytokines and chemokines production was analyzed by CBA (n = 3). The data represent the results of three independent experiments (mean ± SD). \*\* P < 0.01, \*\*\* P < 0.001.

Fig 3. TLR-mediated signaling in MEDMC-BRC6 cells

Flow cytometric analyses of the expression of TLR2 (A) and TLR4 (B) on MEDMC-BRC6 cells and BMMCs. The cells were stimulated with Pam2CSK4 (C) or LPS (D) for 24 h, and then the culture supernatants were analyzed for cytokine production by CBA (n = 3). The data represent the results of three independent experiments (mean ± SD). \*\*\* P < 0.001.

Fig 4. MEDMC-BRC6 cells survive for 24 weeks and compensate for the function of MCs in MC-deficient *Kit<sup>W-sh/W-sh</sup>* mice

 $Kit^{W-sh/W-sh}$  mice were transplanted with 2 ×10<sup>7</sup> of GFP-expressing MEDMC-BRC6 cells or 10<sup>7</sup> of BMCMs. Flow cytometric analyses of FceRI<sup>+</sup>c-Kit<sup>+</sup> MCs in the PEC (A) and the ear skin (B) were analyzed at 12 or 24 weeks after the transplantation. The numbers indicate the proportion of FceRI<sup>+</sup>c-Kit<sup>+</sup> MCs in CD11b<sup>-</sup> cells (A) and CD45<sup>+</sup> CD11b<sup>-</sup> cells (B). The data are shown as 5% probability contour plots. Tissues from stomachs were stained with toluidine blue (C) or with alcian blue followed by safranin O (D) at 12 weeks after the transplantation. Original magnification: ×400. Arrowheads indicate the MCs (E) The rectal temperatures of C57BL/6 mice (n = 2/group) and  $Kit^{W-sh/W-sh}$ mice transplanted with (MEDMC-BRC6  $\rightarrow Kit^{W-sh/W-sh}$ ; n = 3/group) or without MEDMC-BRC6 cells ( $Kit^{W-sh/W-sh}$  mice; n = 3/group). At 24 weeks after the transfer, the mice were sensitized with mouse IgE anti-TNP (20 µg), then challenged with TNP<sub>6</sub>-OVA (1 mg). The data represent the results of two independent experiments (mean ± SEM). \* P < 0.05 as compared with values for  $Kit^{W-sh/W-sh}$  mice by ANOVA.

#### Figure 1. The morphology of MEDMC-BRC6 cells



#### Figure 2. FccRI-mediated signaling in MEDMC-BRC6 cells.



Figure 3. TLR-mediated signaling in MEDMC-BRC6 cells.







Time after challenge (min)